A 32-year-old multiparous woman at 28 weeks of gestation is diagnosed with gestational diabetes mellitus (GDM) following a 75-g OGTT. She is counselled on dietary modification and begins home glucose monitoring. Her fasting glucose readings over 2 weeks are consistently 110–125 mg/dL, and 2-hour postprandial readings are 160–175 mg/dL, despite strict adherence to a low glycemic index diet. She has no contraindications to pharmacotherapy. Which agent is most appropriate as first-line pharmacotherapy for this patient?

Explanation

## Pharmacotherapy for Gestational Diabetes ### First-Line Agent After Dietary Failure **Key Point:** When dietary modification fails to achieve target glucose levels in GDM, **insulin is the gold-standard first-line pharmacotherapy** because it has the longest safety record in pregnancy and does not cross the placenta significantly. ### Comparison of Agents in GDM | Agent | Mechanism | Placental Transfer | Fetal Risk | Use in GDM | |---|---|---|---|---| | **Insulin** | Exogenous glucose control | Minimal | None | **First-line** | | **Metformin** | Reduces hepatic glucose production | Minimal | Emerging data; generally safe | Second-line alternative | | **Glyburide** | Stimulates pancreatic β-cells | Minimal | Neonatal hypoglycemia risk | Avoid; teratogenic in 1st trimester | | **Acarbose** | α-glucosidase inhibitor | Negligible | Minimal | Limited data; not preferred | ### Why Insulin Is Preferred 1. **Longest safety record:** Used in pregnancy for >50 years with extensive safety data 2. **No placental transfer:** Insulin is a large polypeptide; does not cross the placenta 3. **Rapid glycemic control:** Achieves target glucose in days to weeks 4. **No teratogenic risk:** Safe throughout pregnancy, including first trimester 5. **Predictable pharmacokinetics:** Dose can be titrated precisely **High-Yield:** Insulin is the **only agent recommended as first-line pharmacotherapy** for GDM when diet fails. Metformin may be offered as an alternative if patient refuses insulin, but it is not preferred. ### Insulin Regimen in GDM - **Basal-bolus regimen:** NPH (intermediate-acting) or long-acting analog (glargine, detemir) + rapid-acting before meals - **Target fasting glucose:** <95 mg/dL - **Target 2-hour postprandial:** <120 mg/dL - **Monitoring:** Fasting and postprandial glucose; HbA1c every 4 weeks **Clinical Pearl:** Tight glycemic control in GDM reduces macrosomia (birth weight >4000 g) by 50% and neonatal hypoglycemia by 60%. ### Why Other Agents Are Not First-Line - **Metformin:** Emerging evidence supports safety, but insulin remains gold-standard; metformin is a reasonable alternative if patient declines insulin - **Glyburide:** Stimulates fetal pancreatic β-cells → risk of neonatal hypoglycemia; also teratogenic in first trimester - **Acarbose:** Limited safety data in pregnancy; not recommended as first-line [cite:ACOG Practice Bulletin 190, Endocrine Society Clinical Practice Guidelines 2013]